Archive for April 23, 2011

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study

Journal of Antimicrobial Chemotherapy April 2011 V.66  N.suppl 3

Ronald N. Jones*, David J. Farrell, Rodrigo E. Mendes and Helio S. Sader

JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA



To document the spectrum of activity of ceftaroline, the active form of the prodrug, ceftaroline fosamil, a new cephalosporin with anti-methicillin-resistant staphylococcal activity, against a surveillance collection of clinical isolates obtained from theUSAandEuropeduring 2008–09.


A selected group of species associated with community-acquired pneumonia (CAP; 6496 of 17 326 monitored strains) were tested for susceptibility in a central laboratory using CLSI broth microdilution methods. Organisms were sampled from 55 medical centres,27 intheUSAand 28 (12 countries) inEurope. Ceftaroline and comparator agents were tested and interpretations of MIC endpoints made by applying current CLSI (2010) and EUCAST (2010) breakpoint criteria.


Against 1340 Streptococcus pneumoniae, ceftaroline inhibited all isolates at ≤0.5 mg/L (MIC50/90, ≤0.008/0.12 mg/L) and was 8-fold more active than ceftriaxone (MIC90, 1 mg/L; only 79.2% coverage at EUCAST breakpoint). Haemophilus influenzae (n = 584; MIC50/90, ≤0.008/0.015 mg/L), Moraxella catarrhalis (n = 377; MIC50/90, 0.03–0.06/0.12 mg/L) and Staphylococcus aureus (n = 590; MIC50/90, 0.5/1 mg/L) were very susceptible to ceftaroline, regardless of β-lactamase production or multidrug resistance (MDR) patterns. The potency of ceftaroline against three species of Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae) was similar to that of ceftriaxone, ceftazidime and piperacillin/tazobactam. Only modest differences in rates of ceftaroline susceptibility (breakpoint ≤2 mg/L) were noted with extended-spectrum β-lactamase-negative Enterobacteriaceae strains between theUSAandEurope(97.9% versus 97.0% for E. coli). Ceftaroline, like ceftriaxone, was not active against ceftazidime-resistant E. coli (10.2%–26.2% susceptible at ≤2 mg/L) or K. pneumoniae (5.3%–11.2%).


The ceftaroline surveillance for 2008–09 (USAandEurope) documented low MIC50/90 values for S. aureus isolates at 0.5/1 and 0.25/1 mg/L, respectively. More importantly, ceftaroline MIC90 results for S. pneumoniae (0.12 mg/L), H. influenzae (0.015 mg/L) and M. catarrhalis (0.12 mg/L) were very low, all MICs being ≤0.5 mg/L. Ceftaroline exhibited promising high potency and wide coverage against Gram-positive and -negative pathogens known to cause CAP, especially isolates of MDR pneumococci and methicillin-resistant S. aureus.



April 23, 2011 at 3:48 pm Leave a comment

A Randomized Factorial Trial Comparing 4 Treatment Regimens in Treatment-Naive HIV-Infected Persons with AIDS and/or a CD4 Cell Count <200 Cells/µL in South Africa

Journal of Infectious Diseases 15 Nov  2010  V.202  N.10 P.1529-1537

The Phidisa II Writing Team for Project Phidisaa

Reprints or correspondence: Dr Michael A. Polis, NIAID/NIH, 6700B Rockledge Dr, Room 1118, Bethesda, MD 20892 (



Few randomized trials comparing antiretroviral therapy (ART) regimens have been conducted in resource-limited settings.


In the Republic of South Africa, antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals >14 years old with a CD4 cell count <200 cells/µL or a prior AIDS diagnosis were randomized to receive efavirenz (EFV) or lopinavir/ritonavir (LPV/r) with either zidovudine (ZDV) plus didanosine (ddI) or stavudine (d4T) plus lamivudine (3TC) in an open-label, 2-by-2 factorial study and followed up for the primary outcome of AIDS or death and prespecified secondary outcomes, including CD4 cell count and viral load changes, treatment discontinuation, and grade 4 events.


In total, 1771 persons were randomized and followed up for a median of 24.7 months. AIDS or death occurred in (1) 163 participants assigned EFV and 157 assigned LPV/r (hazard ratio [HR], 1.04 [95% confidence interval {CI}, 0.84–1.30]) and in (2) 170 participants assigned ZDV+ddI and 150 assigned d4T+3TC (HR, 1.15 [95% CI, 0.93–1.44]). HIV RNA levels were lower (P < .001) and CD4 cell counts were greater (P < .01) over follow-up for d4T+3TC versus ZDV+ddI. Rates of potentially life-threatening adverse events and overall treatment discontinuation were similar for d4T+3TC and ZDV+ddI; however, more participants discontinued d4T because of toxicity (12.6%) than other treatments (<5%).


EFV and LPV/r are effective components of first-line ART. The poorer viral and immune responses with ZDV+ddI and the greater toxicity-associated discontinuation rate with d4T+3TC suggest that these treatments be used cautiously as initial therapy.

Trial registration. identifier: NCT00342355.


April 23, 2011 at 3:46 pm Leave a comment

Antiretroviral Adherence and Development of Drug Resistance Are the Strongest Predictors of Genital HIV-1 Shedding among Women Initiating Treatment

Journal of Infectious Diseases 15 Nov  2010  V.202  N.10 P.1538-1542

Susan M. Graham1,3,5,7, Linnet Masese1,3, Ruth Gitau3, Zahra Jalalian-Lechak2, Barbra A. Richardson1, Norbert Peshu5, Kishor Mandaliya6, James N. Kiarie4, Walter Jaoko3, Jeckoniah Ndinya-Achola3, Julie Overbaugh2 and R. Scott McClelland1,3

1University of Washington, Seattle, Washington

2Fred Hutchinson Cancer Research Center, Seattle, Washington

3University of Nairobi, Nairobi, Kenya

4Kenyatta National Hospital, Nairobi, Kenya

5Kenya Medical Research Institute, Kilifi, Kenya

6Coast Provincial General Hospital, Mombasa, Kenya

7University of Toronto, Toronto, Ontario, Canada


Persistent genital human immunodeficiency virus type 1 (HIV-1) shedding among women receiving antiretroviral therapy (ART) may present a transmission risk. We investigated the associations between genital HIV-1 suppression after ART initiation and adherence, resistance, pretreatment CD4 cell count, and hormonal contraceptive use. First-line ART was initiated in 102 women. Plasma and genital HIV-1 RNA levels were measured at months 0, 3, and 6. Adherence was a strong and consistent predictor of genital HIV-1 suppression (P < .001), whereas genotypic resistance was associated with higher vaginal HIV-1 RNA level at month 6 (P = .04). These results emphasize the importance of adherence to optimize the potential benefits of ART for reducing HIV-1 transmission risk.


April 23, 2011 at 3:44 pm Leave a comment

Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria

Journal of Antimicrobial Chemotherapy  NOV.2010 V.65 N.Suppl.3  P.25-33

Ann Pallett1,* and Kieran Hand2

1Department of Microbiology, Southampton University Hospitals NHS Trust, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK

2Department of Pharmacy, Southampton University Hospitals NHS Trust, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK


Resistance in Gram-negative bacteria has been increasing, particularly over the last 6 years. This is mainly due to the spread of strains producing extended-spectrum β-lactamases (ESBLs) such as CTX-M enzymes or AmpC β-lactamases. Many of the isolates producing these enzymes are also resistant to trimethoprim, quinolones and aminoglycosides, often due to plasmid co-expression of other resistance mechanisms. CTX-M-producing Escherichia coli often occurs in the community and as E. coli is one of the commonest organisms causing urinary tract infections (UTIs) the choice of agents to treat these infections is diminishing. Novel combinations of antibiotics are being used in the community and broad-spectrum agents such as carbapenems are being used increasingly as empirical treatment for severe infections. Of particular concern therefore are reports in theUKof organisms that produce carbapenemases. As resistance is becoming more widespread, prudent use of antimicrobials is imperative and, as asymptomatic bacteriuria is typically benign in the elderly, antibiotics should not be prescribed without clinical signs of UTI. The use of antibiotics as suppressive therapy or long-term prophylaxis may no longer be defensible.



April 23, 2011 at 3:39 pm Leave a comment


April 2011

Posts by Month

Posts by Category